Ongoing Disclosure Notice – Manu Caddie

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Rua Bioscience Limited
Date this disclosure made:
7-Dec-21
Date of last disclosure:
2-Nov-21
Director or senior manager giving disclosure
Full name(s):
Manu Caddie
Name of listed issuer:
Rua Bioscience Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Kaihautu - Head of Innovation and
Regulation of Rua
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary shares in Rua Bioscience
Limited
Nature of the affected relevant interest(s):
Manu is a director and 50%
shareholder of New Zealand
Nutraceuticals Limited (NZNL). NZNL is
a limited partner of Hikurangi Bioactives
Limited Partnership (HBLP) with a 40%
economic interest in HBLP. HBLP is
the registered holder and beneficial
owner of 17,616,591 (before the
transactions) and 17,554,367 (after the
transactions) ordinary shares in Rua
Bioscience Limited.
For that relevant interest-
Number held in class before acquisition or disposal:
7,046,636
Number held in class after acquisition or disposal:
7,021,747
Current registered holder(s):
HBLP
Registered holder(s) once transfers are registered:
HBLP
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
N/A
Class of underlying financial products:
N/A
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
N/A
A statement as to whether the derivative is cash settled or physically settled:
N/A
Maturity date of the derivative (if any):
N/A
Expiry date of the derivative(if any):
N/A
The price specified in the terms of the derivative (if any):
N/A
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative,-
N/A
Parties to the derivative:
N/A
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
N/A
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 5
Details of transactions requiring disclosure-
Date of transaction:
(a) 30 November 2021
(b) 1 December 2021
(c) 2 December 2021
(d) 3 December 2021
(e) 6 December 2021
Nature of transaction: On market sale
Name of any other party or parties to the transaction (if known):Unknown
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
(a) NZ$2,334.72 being 40% of
proceeds of HBLP's sale of 14,592
shares for $5,836.80 (before any fees)
(b) NZ$627.14 being 40% of proceeds
of HBLP's sale of 3,876 shares for
$1,567.84 (before any fees)
(c) NZ$169.92 being 40% of proceeds
of HBLP's sale of 1,062 shares for
$424.80 (before any fees)
(d) NZ$4,081.28 being 40% of
proceeds of HBLP's sale of 25,508
shares for $10,203.20 (before any
fees)
(e) NZ$2,749.76 being 40% of
proceeds of HBLP's sale of 17,186 for
$6,874.40 (before any fees)
Number of financial products to which the transaction related:
(a) 5,837 (being 40% of 14,592)
(b) 1,550 (being 40% of 3,876)
(c) 425 (being 40% of 1,062)
(d) 10,203 (being 40% of 25,508)
(e) 6,874 (being 40% of 17,186)
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—

Whether relevant interests were acquired or disposed of during a closed period:
Yes. Note, however, that Manu
Caddie does not have control over
HBLP's operational decisions as to
whether to undertake these trades in
Rua's shares.
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
No. Prior written clearance was not
required as Manu Caddie does not
have control over HBLP's operational
decisions as to whether to undertake
these trades in Rua's shares.
Date of the prior written clearance (if any):
N/A
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Ordinary shares in Rua Bioscience
Limited
Nature of relevant interest:Registered and beneficial holder
For that relevant interest,-
Number held in class:194,106
Current registered holder(s):Manu Caddie
For a derivative relevant interest,-
Type of derivative:N/A
Details of derivative
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
N/A
A statement as to whether the derivative is cash settled or physically settled:
N/A
Maturity date of the derivative (if any):
N/A
Expiry date of the derivative (if any):
N/A
The price's specified terms (if any):
N/A
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest,-
N/A
Parties to the derivative:
N/A
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
N/A
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons for
whom it is made.
Signature of director or officer:
Date of signature:7-Dec-21
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person: